Convatec plans $1B investment in R&D in the US and UK

Core Insights - Convatec is a leading provider of devices for managing chronic conditions, ranking as the No. 1 provider of disposable infusion sets globally and the top seller of urinary continence products and services in the U.S. [3] - The company generated revenues of $2.3 billion last year and is on track for increased sales in 2025, with infusion care leading growth [4] - Convatec plans to invest over $1 billion in R&D facilities in the U.S. and U.K. over the next decade, with significant expansions in Boston and Manchester [9] Company Performance - Convatec's revenues reached $2.3 billion last year, with North America accounting for 56% of sales in the first half of the year [4] - The company is experiencing growth in sales, particularly in infusion care, which is expected to lead overall business growth in 2025 [4] R&D Investments - Convatec is expanding its R&D facility in Boston, with completion expected by the end of 2025, aiming to enhance lab, testing, and collaboration spaces [6] - The company is relocating its R&D from Deeside, North Wales, to a new facility in Manchester, scheduled to open in 2027, as part of a $650 million investment in the U.K. [7][9] - The Boston expansion will increase capacity by 50%, while the Manchester facility will employ around 200 people, primarily transferring from Deeside [8][9]